October 1 is the date the American Academy of Pediatrics uses as the start of RSV antibody season for most of the continental United States. The policy itself is not new this morning. AAP published the 2026–2027 recommendations on September 2. What changes today is the calendar: clinics are now inside the window when those doses are meant to go into arms.
What RSV does to babies
Respiratory syncytial virus is a common cold virus for older children and adults. In infants it is the leading cause of hospitalization in the United States. CDC figures cited by AAP put yearly hospitalizations in children under 5 at about 50,000 to 80,000. The virus spreads by droplets and contact. Most infections stay mild. The dangerous course is bronchiolitis or pneumonia in the first months of life, when airways are small and a baby cannot clear mucus well.
Before 2023 the only routine tool was palivizumab, a monthly antibody reserved for a narrow high-risk group. Two products then changed the season: nirsevimab, a long-acting antibody given to the infant, and an RSV vaccine given in pregnancy (RSVpreF) so antibodies cross the placenta. Clesrovimab, a second infant antibody, was licensed last summer. AAP says nirsevimab is currently the product indicated for children who still need protection in a second season.
What stayed the same
AAP still recommends RSV immunization for infants under 8 months who are born during or entering their first RSV season, unless they already have documented protection from a maternal vaccine. One path, not both, is the usual plan: either the pregnancy vaccine in the recommended window or the infant antibody after birth. Timing and product choice belong with the obstetric and pediatric clinicians, not a blog.
For most of the continental U.S., AAP says give the monoclonal antibody from October 1 through March 31, with room to shift if a local season runs early or late. Last season stretched into April in some places.
What changed for the second season
The 2026–2027 policy widens who should be offered immunization at 8 through 19 months, entering a second RSV season. The new high-risk list includes children born before 32 weeks, even if they no longer need oxygen or medicine; children with hemodynamically significant congenital heart disease; children with anatomic lung problems or neuromuscular disorders that raise the risk of severe RSV; and children with Down syndrome or other chromosomal differences that raise that risk.
The older second-season list still stands: chronic lung disease of prematurity needing support in the six months before the season, severe immunocompromise, certain cystic fibrosis, and American Indian and Alaska Native children. Sean T. O’Leary, who chairs the AAP RSV subgroup, said the products work very well to prevent RSV and keep infants out of the hospital, and that real-world impact is already visible. The policy statement and technical report are scheduled for the November 2026 issue of Pediatrics.
Where people disagree
The practical fight is not whether RSV hospitalizes infants. It is who pays, and whose schedule a clinic follows. AAP has been talking to insurers about covering the wider second-season groups. A recommendation is not the same as a paid claim. Parents of a child who newly qualifies — a former 30-week preemie who looks well now, or a toddler with Down syndrome — should ask the pediatrician and the plan before assuming the dose is stocked and covered.
A second split is between professional bodies and federal schedules. AAP’s fall package also includes its own 2026–2027 COVID guidance (all children 6 through 23 months; older children at higher risk, with the dose available if a parent wants it) and flu guidance. Those COVID points have not matched every CDC statement this year. RSV is less contested than COVID, but families will still hear different scripts at the pharmacy, the health department, and the pediatric office. The useful question is which product the child’s own clinician recommends, and whether pregnancy vaccination already covered this baby.
A third view, mostly from clinicians watching supply, is operational: antibodies have been easier to get some seasons than others. Opening day does not mean every practice has doses on the shelf on October 1.
What to watch next
Watch whether insurers publish coverage for the expanded 8-to-19-month groups before November, when the Pediatrics issue lands. Watch local season timing: if pediatric wards fill early, clinics may start or extend outside October–March. Watch which infant product a practice actually stocks. Second-season protection, per AAP, currently runs through nirsevimab. And watch hospitalization curves this winter compared with the first two antibody seasons. That is the check on real-world impact.
This is not medical advice. Product, timing, and whether a given child qualifies are decisions for the child’s clinician. Primary sources: AAP HealthyChildren.org, “AAP Releases RSV Immunization Recommendations for 2026-2027 Season” (published September 2, 2026), and the AAP policy statement scheduled for Pediatrics, November 2026.
Comments (0)
No comments yet.
Sign in to comment.